palbociclib: patients on palbociclib combination treatment
Study summary
The main objectives of this study are to describe patient characteristics, treatment patterns and clinical outcomes of patients receiving palbociclib in Swedish clinical practice.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
Patients must meet all of the following inclusion criteria to be eligible for inclusion in the study:
1. One or more (≥1) filled prescription of palbociclib (ATC code: L01XE33)
2. Age ≥18 years at index date
Exclusion Criteria:
There are no exclusion criteria
Primary outcome measure(s)
Proportion of patients on treatment — 01 January 2017 until 30 September 2020 Proportion of patients who have not discontinued treatment will be assessed at various timepoints (Time Frame: treatment start date through end of study \[assessed up to 48 months\])
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
